Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Genetics to Split Stock Next Month

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Tuesday that its board of directors has approved a two-for-one split of the firm's common stock, which will take effect next month.

The Salt Lake City-based molecular diagnostics firm said that the split would be effected in the form of a dividend, which is payable on March 25 to shareholders of record at the close of business on March 9. Under the split, shareholders will receive one additional share for each share held.

As a result of the split, Myriad will have around 95 million shares outstanding.

In addition, the split will alter the number of shares distributed to current shareholders in Myriad Pharmaceuticals, the proposed spinoff of Myriad's drug development business, which is expected to take place in the second quarter. Myriad has initially intended to grant its shareholders a half share of Myriad Pharmaceuticals stock for each share of Myriad Genetics held. Now, the firm expects to issue one quarter of a share in the new entity.

In early Wednesday trade on the Nasdaq, Myriad's shares were up 2 percent at $83.77.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.